Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

First-line avelumab investigated in cisplatin-unfit advanced UC patients

Roberto Iacovelli presents the ARIES trial of frontline avelumab in patients with PD-L1-positive advanced urothelial cancer who are unable to tolerate cisplatin (4:19).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

14-06-2021 | ASCO 2021 | Conference coverage | Video

Pembrolizumab benefit confirmed for cisplatin-ineligible advanced UC patients

30-09-2021 | ESMO 2021 | Conference coverage | News

Five-year IMvigor210 data confirm first-line atezolizumab mUC benefit

06-08-2021 | Urothelial cancer | Feature | Article

At a glance: First-line immunotherapy for advanced urothelial carcinoma

30-05-2020 | ASCO 2020 | News

Maintenance avelumab ‘new standard of care’ for advanced urothelial cancer
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits